Updated Jul 16, 2026
Locklear Lisa has filed 2 SEC Form 4 filings across 1 company in the last 90 days — buying.
Lisa Locklear serves as the Chief Financial Officer of Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicines. She has been involved in various SEC filings related to the company's financial activities.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-07 | LGVN | Longeveron Inc. | F — Tax withholding / forfeiture | 22.5K | $0.73 | $16K |
| 2026-05-05 | LGVN | Longeveron Inc. | A — Grant or award | 250.0K | $0.00 | |
| 2026-04-03 | LGVN | Longeveron Inc. | F — Tax withholding / forfeiture | 13.1K | $1.12 | $15K |
| 2025-10-01 | LGVN | Longeveron Inc. | F — Tax withholding / forfeiture | 11.9K | $0.74 | $9K |
| 2025-08-11 | LGVN | Longeveron Inc. | P — Open-market purchase | 11.8K | — | |
| 2025-07-15 | LGVN | Longeveron Inc. | A — Grant or award | 102.0K | $0.00 | |
| 2025-07-01 | LGVN | Longeveron Inc. | F — Tax withholding / forfeiture | 7.4K | $1.28 | $10K |
| 2024-10-03 | LGVN | Longeveron Inc. | F — Tax withholding / forfeiture | 5.3K | $1.88 | $10K |
Lisa Locklear serves as the Chief Financial Officer of Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicines. She has been involved in various SEC filings related to the company's financial activities.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 2 open-market purchases () and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Locklear Lisa profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.